Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Short-Term Debt issuances (2016 - 2026)

Usana Health Sciences (USNA) has disclosed Short-Term Debt issuances for 9 consecutive years, with $1.6 million as the latest value for Q2 2025.

  • On a quarterly basis, Short-Term Debt issuances rose 938.96% to $1.6 million in Q2 2025 year-over-year; TTM through Sep 2025 was $24.6 million, a 1560.9% increase, with the full-year FY2024 number at $23.7 million, up 1436.12% from a year prior.
  • Short-Term Debt issuances was $1.6 million for Q2 2025 at Usana Health Sciences, down from $23.0 million in the prior quarter.
  • In the past five years, Short-Term Debt issuances ranged from a high of $23.0 million in Q4 2024 to a low of -$60.0 million in Q1 2022.
  • A 4-year average of -$2.0 million and a median of $537000.0 in 2024 define the central range for Short-Term Debt issuances.
  • Biggest YoY gain for Short-Term Debt issuances was 2803.79% in 2024; the steepest drop was 79.47% in 2024.
  • Usana Health Sciences' Short-Term Debt issuances stood at $500000.0 in 2022, then surged by 58.4% to $792000.0 in 2023, then skyrocketed by 2803.79% to $23.0 million in 2024, then plummeted by 93.04% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for USNA's Short-Term Debt issuances are $1.6 million (Q2 2025), $23.0 million (Q4 2024), and -$2000.0 (Q3 2024).